ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Synopsys, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SNPS GlobeNewswire November 09, 2025 NEW YORK, Nov. 09, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and […]

(NASDAQ:TVRD), Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292

TVRD SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics GlobeNewswire November 09, 2025 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or

(NASDAQ:SNPS), Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Synopsys To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Synopsys between December 4, 2024 and September 9, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner

SNPS SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Announces that Synopsys Investors Have Opportunity to Lead Class Action Lawsuit GlobeNewswire November 09, 2025 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Synopsys To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in

(NYSE:AVTR), Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Avantor To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Avantor between March 5, 2024 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner

AVTR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Announces that Avantor Investors Have Opportunity to Lead Class Action Lawsuit GlobeNewswire November 09, 2025 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Avantor To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in

(Other OTC:NJDCY), Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Nidec To Contact Him Directly To Discuss Their Options If you suffered significant losses in Nidec stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at

NJDCY SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Nidec GlobeNewswire November 09, 2025 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Nidec To Contact Him Directly To Discuss Their Options If you suffered significant losses in Nidec stock or options

(NASDAQ:MNPR), WILMETTE, Ill., Nov. 09, 2025 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, is presenting new data and analyses today from the Phase 2 ALXN1840-WD-204 copper balance study at the American Association for the Study of Liver